MADISON, N.J., Aug. 4, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced CogniSense™, a digital cognitive assessment tool that aids in a physician's assessment, diagnosis and care management of individuals with cognitive dysfunction. CogniSense is designed to overcome several limitations of conventional paper-based cognitive assessment, such as lack of objective, easily trackable data over time and integration to electronic health records (EHRs).

"CogniSense addresses a gap in cognitive health assessment today – a lack of digital technology that seamlessly integrates results into a patient's electronic health records to track cognitive function and disease progression over time," said Edward I. Ginns, MD, PhD, medical director, neurology, for Quest Diagnostics. "CogniSense's features enhance the efficiency and ease of cognitive assessment – especially in a primary care setting."

CogniSense is designed to provide healthcare practitioners with a digitized version of the Memory Orientation Assessment Test (MOST) to assess the cognitive health of a patient's brain through the use of memory recall techniques, information comprehension tests, and tablet-based clock drawing that provides assessment of patient's memory, orientation, sequential memory and time. MOST has been shown to have greater sensitivity and specificity than standard, paper-based mini–mental state examination^® (MMSE) and MiniCog tests, based on studies involving more than 3,500 individuals.

Available as an app for the Apple^® iPad™, CogniSense is administered and scored electronically, providing an objective baseline score and progressive scores that can be stored in Care360^®, Quest's lab-ordering platform, and any of nearly 600 electronic health records that connect to Quest. Once established as part of the patient's medical record, results from CogniSense allow clinicians to track and monitor cognitive function of the patient over time.

"Studies show that cognition plays a huge role in how patients take care of all the management of their health," said Harry Jacob, MD, CMO for Primary PartnerCare, an accountable care organization (ACO) based on Long Island, NY, that piloted CogniSense on nearly 300 patients.  "That is why effective digital tools for the assessment of patients at risk for dementia are essential for an ACO."

"CogniSense combines Quest's leadership in neurology laboratory diagnostics and healthcare information technology to represent a new type of clinical testing we call 'integrated diagnostics," said Jay G. Wohlgemuth, MD, senior vice president and chief medical officer, Quest Diagnostics. "Integrated diagnostics will be increasingly important to neurological disease diagnosis, particularly dementia, given the dearth of evidence-based guidelines and reliable technologies for facilitating assessment and diagnosis for the globally aging population."

Quest Diagnostics is championing the development of new integrated diagnostics that combine multiple diagnostic modalities such as cognitive assessment, laboratory testing, imaging, and clinical knowledge to aid in the detection and diagnosis of dementia. Through a collaboration with the University of California, San Francisco (UCSF) Memory and Aging Center, Quest Diagnostics is also facilitating the development of evidence-based standards for screening, diagnosis, and monitoring of people with dementia to help improve outcomes and better address the needs of the nation's aging population.

CogniSense was unveiled during the Alzheimer's Association International Conference (AAIC) in Toronto in July 2016 and is available to download from the Apple^® iTunes™ Store by searching for "CogniSense." For more information please visit www.QuestCogniSense.com. A Quest Care360 account is obtainable at no cost for qualified healthcare providers at http://get.care360.com.

About Dementia
Dementia is characterized by a decline in memory, language, problem-solving and cognitive functioning, and is often unrecognized in affected patients. Up to 5.5 million Americans have dementia such as Alzheimer's disease, and this number is projected to almost triple by 2050. The Alzheimer's Association predicts costs associated with dementia will reach more than $1 trillion in 2050. Research suggests that many patients are never diagnosed. Early detection helps patients and families make long-term care plans, and helps physicians better manage a patient's comorbid conditions, avoid prescribing medications that may worsen function, and facilitates access to therapies that may slow progression.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 44,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com

Quest, Quest Diagnostics, Athena Diagnostics and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics.

Contacts:
Wendy Bost, Quest Diagnostics (Media): 973-520-2800
Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900

Logo - http://photos.prnewswire.com/prnh/20150422/200883LOGO

SOURCE Quest Diagnostics